The company specializes in the development of compounds that promote the growth of new neurons to treat major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer's disease (AD). Their products, such as BCI-838 and BCI-632, work by increasing synaptic glutamate through the inhibition of the mGlu2/3 auto-receptor. Additionally, BrainCells is actively building a pipeline of clinical-stage programs to address various unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. Founded in 2003 and based in San Diego, California, BrainCells utilizes its neurogenesis technology platform to identify compounds and targets optimal for CNS indications.